

CoC Measures for Quality of Cancer Care

A - Accountability; QI - Quality Improvement; S- Surveillance

Primary Site	Measure Type	2016 Standard and Expected EPR	Measure Description: Data from 2011 thru 2014	Initial CP3R Release
Bladder				
BL2RLN	S	Not Applicable	At least 2 lymph nodes are removed in patients under 80 undergoing partial or radical cystectomy No data for this measure at HRH	Spring 2016
Breast	<u>HRH compliant with all Breast Measures</u>			
BCSRT	A	Standard 4.4 90%	(NQF #219) Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. <u>Exceeded standard, 100% in 2011, 96% in 2012, 94 % in 2013 and 95% in 2014</u>	Fall 2008
MAC	A	Not Applicable	(NQF #0559) Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or stage IB - III hormone receptor negative breast cancer. <u>HRH at 100% all 4 years.</u>	Fall 2008
HT	A	Standard 4.4 90%	(NQF #0220) Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer. <u>Exceeding standard, 100% in 2011, 92% in 2012, 87% in 2013 and 100% in 2014</u>	Fall 2008
MASTRT	A	Standard 4.4 90%	Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes. <u>Exceeding Standard, HRH at 100% all 4 years</u>	Spring 2014
nBx	QI	Standard 4.5 80%	Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer. <u>Exceeding standard, 97% in 2011, 97% in 2012, 92% in 2013 and 100% in 2014</u>	Spring 2014
BCS	S	Not Applicable	Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. <u>HRH at 70 % in 2011, at 96 % in 2012, at 90% in 2013 and at</u>	Spring 2014

			88% in 2014.	
Cervix				
CBRRT	S	Not Applicable	Use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer <u>No data for this measure at HRH</u>	Spring 2015
CERRT	S	Not Applicable	Radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer: No data in 2011, <u>HRH at 100% for 2012 – 2014.</u>	Spring 2015
CERCT	S	Not Applicable	Chemotherapy administered to cervical cancer patients who received radiation for stages IB2-IV cancer (Group 1) or with positive pelvic nodes, positive surgical margin, and/or positive parametrium (Group 2): No data for 2011, <u>HRH at 50% in 2012, and at 100% in 2013 and 2014.</u>	Fall 2015
Colon				
ACT	A	Not Applicable	(NQF #0223) Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer. <u>HRH at 100% for 2011-2013 and at 75% in 2014.</u>	Fall 2008
12RLN	QI	Standard 4.5 85%	(NQF #0225) At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. <u>HRH at 82% for 2011, 93% in 2012, 100% in 2013 and at 72% in 2014.</u>	Fall 2008
Endometrium				
ENDCTRTR	S	Not Applicable	Chemotherapy and/or radiation administered to patients with Stage IIIC or IV Endometrial cancer <u>No data for this measure at HRH</u>	Fall 2015
ENDLRC	S	Not Applicable	Endoscopic, laparoscopic, or robotic surgery performed for all Endometrial cancer (excluding sarcoma and lymphoma), for all stages except stage IV: No data for 2011, <u>HRH at 100% in 2012.</u> No data for 2013 or 2014.	Fall 2015
Gastric				
G15RLN	QI	Standard 4.5 80%	At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer. <u>No data for this measure at HRH</u>	Fall 2014
Non-Small Cell Lung				
10RLN	S	Not	At least 10 regional lymph nodes are removed and pathologically examined for	Fall

		Applicable	AJCC stage IA, IB, IIA, and IIB resected NSCLC; <u>No data for this measure at HRH</u>	2014
LCT	QI	Standard 4.5 85%	Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC. No data in 2012. <u>Exceeded Standard 100% in 2011 and 2013</u> , no data in 2014	Fall 2014
LNoSurg	QI	Standard 4.5 85%	Surgery is not the first course of treatment for cN2, M0 lung cases <u>Exceeded Standard 100% for all 4 years</u>	Spring 2015
Ovary				
OVSAL	S	Not Applicable	Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration in Stages I-IIIc Ovarian cancer <u>No data for this measure at HRH</u>	Fall 2015
Rectum				
RECRCT	QI	Standard 4.5 85%	Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer. <u>HRH exceeding standard for 2011-2013 at 100%, 67 % in 2014</u>	Spring 2015

A - Accountability; QI - Quality Improvement; S- Surveillance